The authors found no significant differences in progression-free survival (PFS), overall survival (OS), and treatment toxicity between the two treated groups, which implies that either high-grade gliomas are less responsive to the time-based delivery of the radiotherapy, or that the patients in the different groups (morning vs afternoon) were not treated at their optimal treatment time, according to their circadian clock. This evidence concerns the gene CLOCK and glioma.